Evaluating Trastuzumab in the treatment of HER2 positive breast cancer.
Animals
Antineoplastic Agents, Immunological
/ adverse effects
Biomarkers, Tumor
/ antagonists & inhibitors
Breast Neoplasms
/ drug therapy
Cardiotoxicity
Drug Resistance, Neoplasm
Female
Heart Diseases
/ chemically induced
Humans
Receptor, ErbB-2
/ antagonists & inhibitors
Signal Transduction
Trastuzumab
/ adverse effects
Treatment Outcome
Journal
Histology and histopathology
ISSN: 1699-5848
Titre abrégé: Histol Histopathol
Pays: Spain
ID NLM: 8609357
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
pubmed:
24
4
2020
medline:
2
10
2021
entrez:
24
4
2020
Statut:
ppublish
Résumé
The transmembrane oncoprotein HER2 is encoded by ERBB2 gene and overexpressed in around 20% of invasive breast cancers. It can be specifically targeted by Trastuzumab (Herceptin®), a humanised IgG1 antibody. Trastuzumab has been regarded as one of the most effective therapeutic drugs targeted to HER2 positive cancers. However, there are drawbacks, notably cardiotoxicity and resistance, which have raised awareness in clinical use. Therefore, understanding the mechanism of action is vital to establish improved therapeutic strategies. Here we evaluate Trastuzumab application in the treatment of HER2 positive breast cancer, focusing on its mechanistic actions and clinical effectiveness. Alternative therapies targeting the HER2 receptor and its downstream anomalies will also be discussed, as these could highlight further targets that could be key to improving clinical outcomes.
Identifiants
pubmed: 32323293
pii: HH-18-221
doi: 10.14670/HH-18-221
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Biomarkers, Tumor
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1059-1075Subventions
Organisme : -
ID : -
Références
Arnal-Estape A., Tarragona M., Morales M., Guiu M., Nadal C., Massague J. and Gomis R.R. (2010). HER2 silences tumor suppression in breast cancer cells by switching expression of C/EBPss isoforms. Cancer Res. 70, 9927-9936.
pubmed: 21098707
Arribas J., Baselga J., Pedersen K. and Parra-Palau J.L. (2011). p95HER2 and breast cancer. Cancer Res. 71, 1515-1519.
pubmed: 21343397
Austin C.D., De Maziere A.M., Pisacane P.I., van Dijk S.M., Eigenbrot C., Sliwkowski M.X., Klumperman J. and Scheller R.H. (2004). Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol. Biol. Cell. 15, 5268-5282.
pmcid: PMC532009
pubmed: 15385631
Awada A., Colomer R., Inoue K., Bondarenko I., Badwe R.A., Demetriou G., Lee S.C., Mehta A.O., Kim S.B., Bachelot T., Goswami C., Deo S., Bose R., Wong A., Xu F., Yao B., Bryce R. and Carey L.A. (2016). Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: The NEfERT-T randomized clinical trial. JAMA Oncol. 2, 1557-1564.
pubmed: 27078022
Balduzzi S., Mantarro S., Guarneri V., Tagliabue L., Pistotti V., Moja L. and D'Amico R. (2014). Trastuzumab‐containing regimens for metastatic breast cancer. Cochrane Database Syst. Rev. 6, CD006242.
pmcid: PMC6464904
pubmed: 24919460
Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., Lordick F., Ohtsu A., Omuro Y., Satoh T., Aprile G., Kulikov E., Hill J., Lehle M., Rüschoff J., Kang Y.K. and ToGA. Trial Investigators. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2- positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687-697.
pubmed: 20728210
Bersell K., Arab S., Haring B. and Kuhn B. (2009). Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 138, 257-270.
pubmed: 19632177
Blackwell K.L., Burstein H.J., Storniolo A.M., Rugo H., Sledge G., Koehler M., Ellis C., Casey M., Vukelja S., Bischoff J., Baselga J. and O'Shaughnessy J. (2010). Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol. 28, 1124-1130.
pubmed: 20124187
Boekhout A.H., Gietema J.A., Milojkovic Kerklaan B., van Werkhoven E.D., Altena R., Honkoop A., Los M., Smit W.M., Nieboer P., Smorenburg C.H., Mandigers C.M., van der Wouw A.J., Kessels L., van der Velden A.W., Ottevanger P.B., Smilde T., de Boer J., van Veldhuisen D.J., Kema I.P., de Vries E.G. and Schellens J.H. (2016). Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: A randomized clinical trial. JAMA Oncol. 2, 1030-1037.
pubmed: 27348762
Bostrom P., Mann N., Wu J., Quintero P.A., Plovie E.R., Panakova D., Gupta R.K., Xiao C., MacRae C.A., Rosenzweig A. and Spiegelman B.M. (2010). C/EBPbeta controls exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell 143, 1072-1083.
pmcid: PMC3035164
pubmed: 21183071
Buzdar A.U., Valero V., Ibrahim N.K., Francis D., Broglio K.R., Theriault R.L., Pusztai L., Green M.C., Singletary S.E., Hunt K.K., Sahin A.A., Esteva F., Symmans W.F., Ewer M.S., Buchholz T.A. and Hortobagyi G.N. (2007). Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin. Cancer Res. 13, 228- 233.
pubmed: 17200359
Cai H. and Harrison D.G. (2000). Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 87, 840-844.
pubmed: 11073878
Cameron D., Piccart-Gebhart M.J., Gelber R.D., Procter M., Goldhirsch A., de Azambuja E., Castro G. Jr, Untch M., Smith I., Gianni L., Baselga J., Al-Sakaff N., Lauer S., McFadden E., Leyland-Jones B., Bell R., Dowsett M., Jackisch C. and HERA Trial Study Team. (2017). 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389, 1195-1205.
pmcid: PMC5465633
pubmed: 28215665
Chen S.C., Quartino A., Polhamus D., Riggs M., French J., Wang X., Vadhavkar S., Smitt M., Hoersch S., Strasak A., Jin J.Y., Girish S. and Li C. (2017). Population pharmacokinetics and exposureresponse of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens. Br. J. Clin. Pharmacol. 83, 2767-2777.
pmcid: PMC5698565
pubmed: 28733983
Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., Wolter J.M., Paton V., Shak S., Lieberman G. and Slamon D.J. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639- 2648.
pubmed: 10561337
Collins D.M., O'Donovan N., McGowan P.M., O'Sullivan F., Duffy M.J. and Crown J. (2012). Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann. Oncol. 23, 1788-1795.
pubmed: 22056974
Conraads V.M., Deaton C., Piotrowicz E., Santaularia N., Tierney S., Piepoli M.F., Pieske B., Schmid J.P., Dickstein K., Ponikowski P.P. and Jaarsma T. (2012). Adherence of heart failure patients to exercise: barriers and possible solutions: a position statement of the Study Group on Exercise Training in Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart. Fail. 14, 451-458.
pubmed: 22499542
Coussens L.M., Zitvogel L. and Palucka A.K. (2013). Neutralizing tumorpromoting chronic inflammation: a magic bullet? Science 339, 286- 291.
pmcid: PMC3591506
pubmed: 23329041
Dai C.L., Tiwari A.K., Wu C.P., Su X.D., Wang S.R., Liu D.G., Ashby C.R. Jr., Huang Y., Robey R.W., Liang Y.J., Chen L.M., Shi C.J., Ambudkar S.V., Chen Z.S. and Fu L.W. (2008). Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res. 68, 7905-7914.
pmcid: PMC2652245
pubmed: 18829547
Dasgupta S., Wasson L.M., Rauniyar N., Prokai L., Borejdo J. and Vishwanatha J.K. (2009). Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells. Oncogene 28, 2860-2872.
pmcid: PMC2726905
pubmed: 19503095
Denny E.C. and Kane S.E. (2015). t-Darpp promotes enhanced EGFR activation and new drug synergies in Her2-positive breast cancer cells. PLoS One 10, 0132267.
pmcid: PMC4488293
pubmed: 26121470
Depowski P.L., Rosenthal S.I. and Ross J.S. (2001). Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod. Pathol. 14, 672-676.
pubmed: 11454999
Dieras V., Miles D., Verma S., Pegram M., Welslau M., Baselga J., Krop I.E., Blackwell K., Hoersch S., Xu J., Green M. and Gianni L. (2017). Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 18, 732-742.
pmcid: PMC5531181
pubmed: 28526536
Durrani S., Akbar S. and Heena H. (2018). Breast cancer during pregnancy. Cureus 10, 2941.
pmcid: PMC6128597
pubmed: 30202672
Eberlein C., Kendrew J., McDaid K., Alfred A., Kang J.S., Jacobs V.N., Ross S.J., Rooney C., Smith N.R., Rinkenberger J., Cao A., Churchman A., Marshall J.F., Weir H.M., Bedian V., Blakey D.C., Foltz I.N. and Barry S.T. (2013). A human monoclonal antibody 264RAD targeting alphavbeta6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo. Oncogene 32, 4406-4416.
pubmed: 23108397
Ewer M.S. and Ewer S.M. (2015). Cardiotoxicity of anticancer treatments. Nat. Rev. Cardiol. 12, 547-558.
pubmed: 25962976
Fabi A., Malaguti P., Vari S. and Cognetti F. (2016). First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces? J. Exp. Clin. Cancer Res. 35, 104.
pmcid: PMC4928292
pubmed: 27357210
Galanti G., Stefani L. and Gensini G. (2013). Exercise as a prescription therapy for breast and colon cancer survivors. Int. J. Gen. Med. 6, 245-251.
pmcid: PMC3633577
pubmed: 23620675
Gasparini G., Gion M., Mariani L., Papaldo P., Crivellari D., Filippelli G., Morabito A., Silingardi V., Torino F., Spada A., Zancan M., De Sio L., Caputo A., Cognetti F., Lambiase A. and Amadori D. (2007). Randomized phase II trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res. Treat. 101, 355-365.
pubmed: 16850247
Gianni L., Eiermann W., Semiglazov V., Manikhas A., Lluch A., Tjulandin S., Zambetti M., Vazquez F., Byakhow M., Lichinitser M., Climent M.A., Ciruelos E., Ojeda B., Mansutti M., Bozhok A., Baronio R., Feyereislova A., Barton C., Valagussa P. and Baselga J. (2010). Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375, 377-384.
pubmed: 20113825
Gianni L., Dafni U., Gelber R.D., Azambuja E., Muehlbauer S., Goldhirsch A., Untch M., Smith I., Baselga J., Jackisch C., Cameron D., Mano M., Pedrini J.L., Veronesi A., Mendiola C., Pluzanska A., Semiglazov V., Vrdoljak E., Eckart M.J., Shen Z., Skiadopoulos G., Procter M., Pritchard K.I., Piccart-Gebhart M.J., Bell R. and HERA Trial Study Team. (2011). Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 12, 236-244.
pubmed: 21354370
Goss P.E., Smith I.E., O'Shaughnessy J., Ejlertsen B., Kaufmann M., Boyle F., Buzdar A.U., Fumoleau P., Gradishar W., Martin M., Moy B., Piccart-Gebhart M., Pritchard K.I., Lindquist D., Chavarri-Guerra Y., Aktan G., Rappold E., Williams L.S., Finkelstein D.M. and TEACH investigators. (2013). Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol. 14, 88-96.
pubmed: 23234763
Gu L., Waliany S. and Kane S.E. (2009). Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance. PLoS One 4, 6220.
pmcid: PMC2704867
pubmed: Gu L., Waliany S. and Kane S.E. (2009). Darpp-32 and its truncated
variant t-Darpp have antagonistic effects on breast cancer cell
growth and herceptin resistance. PLoS One 4, 6220.
Guglin M., Munster P., Fink A. and Krischer J. (2017). Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial. Am. Heart. J. 188, 87-92.
pmcid: PMC5458618
pubmed: 28577685
Harbeck N., Beckmann M.W., Rody A., Schneeweiss A., Muller V., Fehm T., Marschner N., Gluz O., Schrader I., Heinrich G., Untch M. and Jackisch C. (2013). HER2 dimerization inhibitor pertuzumab - mode of action and clinical data in breast cancer. Breast Care (Basel). 8, 49-55.
pmcid: PMC3971793
pubmed: 24715843
Haykowsky M.J., Mackey J.R., Thompson R.B., Jones L.W. and Paterson D.I. (2009). Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training. Clin. Cancer Res. 15, 4963-4967.
pubmed: 19622583
Huober J., Fasching P.A., Barsoum M., Petruzelka L., Wallwiener D., Thomssen C., Reimer T., Paepke S., Azim H.A., Ragosch V., Kubista E., Baumgärtner A.K., Beckmann M.W., May C., Nimmrich I. and Harbeck N. (2012). Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. Breast 21, 27-33.
pubmed: 21862331
Hurvitz S.A., Martin M., Symmans W.F., Jung K.H., Huang C.S. and Thompson A.M. (2018). Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 19, 115-126.
pubmed: 29175149
Iqbal N. and Iqbal N. (2014). Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications. Mol. Biol. Int. 852748.
pmcid: PMC4170925
pubmed: 25276427
Joensuu H., Bono P., Kataja V., Alanko T., Kokko R., Asola R., Utriainen T., Turpeenniemi-Hujanen T., Jyrkkiö S., Möykkynen K., Helle L., Ingalsuo S., Pajunen M., Huusko M., Salminen T., Auvinen P., Leinonen H., Leinonen M., Isola J. and Kellokumpu-Lehtinen P.L. (2009). Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J. Clin. Oncol. 27, 5685-5692.
pubmed: 19884557
Joensuu H., Fraser J., Wildiers H., Huovinen R., Auvinen P., Utriainen M., Nyandoto P., Villman K.K., Halonen P., Granstam-Björneklett H., Lundgren L., Sailas L., Turpeenniemi-Hujanen T., Tanner M., Yachnin J., Ritchie D., Johansson O., Huttunen T., Neven P., Canney P., Harvey V., Kellokumpu-Lehtinen P.L. and Lindman H. (2018). Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: The SOLD randomized clinical trial. JAMA Oncol. 4, 1199-1206.
pmcid: PMC6143012
pubmed: 29852043
Jones L.W., Liang Y., Pituskin E.N., Battaglini C.L., Scott J.M., Hornsby W.E. and Haykowsky M. (2011). Effect of exercise training on peak oxygen consumption in patients with cancer: a meta-analysis. Oncologist 16, 112-120.
pmcid: PMC3228052
pubmed: 21212429
Jones L.W., Watson D., Herndon J.E., Eves N.D., Haithcock B.E., Loewen G. and Kohman L. (2010). Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer. Cancer 116, 4825-4832.
pmcid: PMC5399980
pubmed: 20597134
Katz E., Dubois-Marshall S., Sims A.H., Faratian D., Li J., Smith E.S., Quinn J.A., Edward M., Meehan R.R., Evans E.E., Langdon S.P. and Harrison D.J. (2010). A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk. Br. J. Cancer 103, 401-410.
pmcid: PMC2920017
pubmed: 20628393
Kaufman B., Mackey J.R., Clemens M.R., Bapsy P.P., Vaid A., Wardley A., Tjulandin S., Jahn M., Lehle M., Feyereislova A., Révil C. and Jones A. (2009). Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptorpositive metastatic breast cancer: results from the randomized phase III TAnDEM study. J. Clin. Oncol. 27, 5529-5537.
pubmed: 19786670
Kavanagh T., Mertens D.J., Hamm L.F., Beyene J., Kennedy J., Corey P. and Shephard R.J. (2003). Peak oxygen intake and cardiac mortality in women referred for cardiac rehabilitation. J. Am. Coll. Cardiol. 42, 2139-2143.
pubmed: 14680741
Kelsey C.R., Scott J.M., Lane A., Schwitzer E., West M.J., Thomas S., Herndon J.E., Michalski M.G., Horwitz M.E., Hennig T. and Jones L.W. (2014). Cardiopulmonary exercise testing prior to myeloablative allo-SCT: a feasibility study. Bone Marrow Transplant. 49, 1330- 1336.
pmcid: PMC4516174
pubmed: 25068429
Kim I.M., Tilley D.G., Chen J., Salazar N.C., Whalen E.J., Violin J.D. and Rockman H.A. (2008). Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc. Natl. Acad. Sci. USA 105, 14555-14560.
pmcid: PMC2567217
pubmed: 18787115
Kirkham A.A., Bonsignore A., Bland K.A., McKenzie D.C., Gelmon K.A., Van Patten C.L. and Campbell K.L. (2018). Exercise prescription and adherence for breast cancer: One size does not FITT all. Med. Sci. Sports Exerc. 50177-50186.
pubmed: 28991038
Kirkham A.A., Campbell K.L. and McKenzie D.C. (2013). Comparison of aerobic exercise intensity prescription methods in breast cancer. Med. Sci. Sports Exerc. 45, 1443-1450.
pubmed: 23439424
Krstic J. and Santibanez J.F. (2014). Transforming growth factor-beta and matrix metalloproteinases: functional interactions in tumor stroma-infiltrating myeloid cells. Sci. World J. 521754.
pmcid: PMC3918721
pubmed: 24578639
Lakoski S.G., Willis B.L., Barlow C.E., Leonard D., Gao A., Radford N.B., Farrell S.W., Douglas P.S., Berry J.D., DeFina L.F. and Jones L.W. (2015). Midlife cardiorespiratory fitness, incident cancer, and survival after cancer in men: The cooper center longitudinal study. JAMA Oncol. 1, 231-237.
pmcid: PMC5635343
pubmed: 26181028
Lambertini M., Martel S., Campbell C., Guillaume S., Hilbers F.S., Schuehly U., Korde L., Azim H.A. Jr., Di Cosimo S., Tenglin R.C., Huober J., Baselga J., Moreno-Aspitia A., Piccart-Gebhart M., Gelber R.D., de Azambuja E. and Ignatiadis M. (2019). Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials. Cancer 125, 307-316.
pubmed: 30335191
Lamy P.J., Fina F., Bascoul-Mollevi C., Laberenne A.C., Martin P.M., Ouafik L. and Jacot W. (2011). Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. Breast Cancer Res. 13, R15.
pmcid: PMC3109584
pubmed: 21288332
Le X.F., Pruefer F. and Bast R.C. Jr (2005) HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle 4, 87-95.
pubmed: 15611642
Lenz G., Hamilton A., Geng S., Hong T., Kalkum M., Momand J., Kane S.E. and Huss J.M. (2018). t-Darpp activates IGF-1R signaling to regulate glucose metabolism in trastuzumab-resistant breast cancer cells. Clin. Cancer Res. 24, 1216-1226.
pmcid: PMC7007690
pubmed: 29180608
Liu X., Gu X., Li Z., Li X., Li H., Chang J., Chen P., Jin J., Xi B., Chen D., Lai D., Graham R.M. and Zhou M. (2006). Neuregulin-1/erbBactivation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J. Am. Coll. Cardiol. 48, 1438-1447.
pubmed: 17010808
Luque-Cabal M., Garcia-Teijido P., Fernandez-Perez Y., Sanchez- Lorenzo L. and Palacio-Vazquez I. (2016). Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome it. Clin. Med. Insights Oncol. 10, 21-30.
pmcid: PMC4811269
pubmed: 27042153
Martin M., Bonneterre J., Geyer C.E. Jr, Ito Y., Ro J., Lang I., Kim S.B., Germa C., Vermette J., Wang K., Wang K. and Awada A. (2013). A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur. J. Cancer 49, 3763-3772.
pubmed: 23953056
Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana- Hulin M., Chan S., Grimes D., Antón A., Lluch A., Kennedy J., O'Byrne K., Conte P., Green M., Ward C., Mayne K. and Extra J.M. (2005). Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol. 23, 4265-4274.
pubmed: 15911866
Mayor S. (2006). NICE approves trastuzumab for early stage breast cancer. BMJ 332, 1409.
pmcid: PMC1479684
pubmed: 16777868
Mercogliano M.F., De Martino M., Venturutti L., Rivas M.A., Proietti C.J., Inurrigarro G., Frahm I., Allemand D.H., Deza E.G., Ares S., Gercovich F.G., Guzmán P., Roa J.C., Elizalde P.V. and Schillaci R. (2017). TNFalpha-induced mucin 4 expression elicits trastuzumab resistance in HER2-positive breast cancer. Clin. Cancer Res. 23, 636-648.
pubmed: 27698002
Mitra D., Brumlik M.J., Okamgba S.U., Zhu Y., Duplessis T.T., Parvani J.G., Lesko S.M., Brogi E. and Jones F.E. (2009). An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol. Cancer Ther. 8, 2152-2162.
pubmed: 19671734
Mitri Z., Constantine T. and O'Regan R. (2012). The HER2 receptor in breast cancer: Pathophysiology, clinical use, and new advances in therapy. Chemother. Res. Pract. 743193.
pmcid: PMC3539433
pubmed: 23320171
Moasser M.M. (2007). The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26, 6469-6487.
pmcid: PMC3021475
pubmed: 17471238
Mohan N., Jiang J. and Wu W.J. (2017). Implications of autophagy and oxidative stress in trastuzumab-mediated cardiac toxicities. Austin Pharmacol. Pharm. 2, 1.
pmcid: PMC6168002
pubmed: 30288503
Moja L., Tagliabue L., Balduzzi S., Parmelli E., Pistotti V., Guarneri V. and D'Amico R. (2012). Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst. Rev. 4, CD006243.
pmcid: PMC6718210
pubmed: 22513938
Moore K.M., Thomas G.J., Duffy S.W., Warwick J., Gabe R., Chou P., Ellis I.O., Green A.R., Haider S., Brouilette K., Saha A., Vallath S., Bowen R., Chelala C., Eccles D., Tapper W.J., Thompson A.M., Quinlan P., Jordan L., Gillett C., Brentnall A., Violette S., Weinreb P.H., Kendrew J., Barry S.T., Hart I.R., Jones J.L. and Marshall J.F. (2014). Therapeutic targeting of integrin alphavbeta6 in breast cancer. J. Natl. Cancer Inst. 106, ju169.
pmcid: PMC4151855
pubmed: 24974129
Morshedi-Meibodi A., Larson M.G., Levy D., O’Donnell C.J. and Vasan R.S. (2002). Heart rate recovery after treadmill exercise testing and risk of cardiovascular disease events (the Framingham Heart Study). Am. J. Cardiol 90, 848-852.
pubmed: 12372572
Naseem S. (2018) "Breaking breast cancer news" with ethnic minority: a UK experience. J. Multidiscip. Healthc. 11, 317-322.
pmcid: PMC6037409
pubmed: 30013358
Oakman C., Pestrin M., Zafarana E., Cantisani E. and Di Leo A. (2010). Role of lapatinib in the first-line treatment of patients with metastatic breast cancer. Cancer Manag. Res. 2, 13-25.
pmcid: PMC3004582
pubmed: 21188093
Osoba D., Slamon D.J., Burchmore M. and Murphy M. (2002). Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J. Clin. Oncol. 20, 3106-3113.
pubmed: 12118024
Padua D. and Massague J. (2009). Roles of TGFbeta in metastasis. Cell Res. 19, 89-102.
pubmed: 19050696
Perez E.A., Barrios C., Eiermann W., Toi M., Im Y.H., Conte P., Martin M., Pienkowski T., Pivot X., Burris H. 3rd., Petersen J.A., Stanzel S., Strasak A., Patre M. and Ellis P. (2017). Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: Primary results from the phase III MARIANNE study. J. Clin. Oncol. 35, 141-148.
pmcid: PMC5455677
pubmed: 28056202
Perez E.A., Romond E.H., Suman V.J., Jeong J.H., Sledge G., Geyer C.E. Jr, Martino S., Rastogi P., Gralow J., Swain S.M., Winer E.P., Colon-Otero G., Davidson N.E., Mamounas E., Zujewski J.A. and Wolmark N. (2014). Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J. Clin. Oncol. 32, 3744-3752.
pmcid: PMC4226805
pubmed: 25332249
Petit A.M., Rak J., Hung M.C., Rockwell P., Goldstein N., Fendly B. and Kerbel R.S. (1997). Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 151, 1523-1530.
pmcid: PMC1858348
pubmed: 9403702
Pituskin E., Mackey J.R., Koshman S., Jassal D., Pitz M., Haykowsky M.J., Pagano J.J., Chow K., Thompson R.B., Vos L.J., Ghosh S., Oudit G.Y., Ezekowitz J.A. and Paterson D.I. (2017). Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J. Clin. Oncol. 35, 870-877.
pubmed: 27893331
Pivot X., Manikhas A., Zurawski B., Chmielowska E., Karaszewska B., Allerton R., Chan S., Fabi A., Bidoli P., Gori S., Ciruelos E., Dank M., Hornyak L., Margolin S., Nusch A., Parikh R., Nagi F., DeSilvio M., Santillana S., Swaby R.F. and Semiglazov V. (2015). CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin. Oncol. 33, 1564-1573.
pubmed: 25605838
Pivot X., Romieu G., Debled M., Pierga J.Y., Kerbrat P., Bachelot T., Lortholary A., Espié M, Fumoleau P., Serin D., Jacquin J.P., Jouannaud C., Rios M., Abadie-Lacourtoisie S., Tubiana-Mathieu N., Cany L., Catala S., Khayat D., Pauporté I., Kramar A. and PHARE trial investigators. (2013). 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 14, 741-748.
pubmed: 23764181
Pohlmann P.R., Mayer I.A. and Mernaugh R. (2009). Resistance to trastuzumab in breast cancer. Clin. Cancer Res. 15, 7479-7491.
pmcid: PMC3471537
pubmed: 20008848
Qiu S., Cai X., Sun Z., Li L., Zuegel M., Steinacker J.M. and Shumann U. (2017). Heart rate recovery and risk of cardiovascular events and all-cause mortality: a meta-analysis of prospective cohort studies. J. Am. Heart Assoc. 6, 005505.
pmcid: PMC5524096
pubmed: 28487388
Rakha E.A., Pinder S.E., Bartlett J.M., Ibrahim M., Starczynski J., Carder P.J., Provenzano E., Hanby A., Hales S., Lee A.H., Ellis I.O. and the National Coordinating Committee for Breast Pathology. (2015). Updated UK Recommendations for HER2 assessment in breast cancer. J. Clin. Pathol. 68, 93-99.
pmcid: PMC4316916
pubmed: 25488926
Romero A., Martin M., Cheang M.C., Lopez Garcia-Asenjo J.A., Oliva B., He X., de la Hoya M., García Sáenz J.Á., Arroyo Fernández M., Díaz Rubio E., Perou C.M. and Caldés Llopis T. (2011). Assessment of Topoisomerase II alpha status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. Am. J. Pathol. 178, 1453-1460.
pmcid: PMC3078442
pubmed: 21435434
Rupert C.E. and Coulombe K.L. (2015). The roles of neuregulin-1 in cardiac development, homeostasis, and disease. Biomark Insights. 10, 1-9.
pmcid: PMC4395047
pubmed: 25922571
Scharhag-Rosenberger F., Kuehl R., Klassen O., Schommer K., Schmidt M.E., Ulrich C.M., Wiskemann J. and Steindorf K. (2015). Exercise training intensity prescription in breast cancer survivors: validity of current practice and specific recommendations. J. Cancer. Surviv. 94, 612-619.
pubmed: 25711667
Schmitz K.H., Courneya K.S., Matthews C., Demark-Wahnefried W., Galvão D.A., Pinto B.M., Irwin M.L., Wolin K.Y., Segal R.J., Lucia A., Schneider C.M., von Gruenigen V.E. and Schwartz A.L. (2010). American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med. Sci. Sports Exerc. 42, 1409- 1426.
pubmed: 20559064
Scholl S., Beuzeboc P. and Pouillart P. (2001). Targeting HER2 in other tumor types. Ann. Oncol. 12, S81-87.
pubmed: 11521727
Schwab C.L., English D.P., Black J., Bellone S., Lopez S., Cocco E., Bonazzoli E., Bussi B., Predolini F., Ferrari F., Ratner E., Silasi D.A., Azodi M., Rutherford T., Schwartz P.E. and Santin A.D. (2015). Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. Gynecol. Oncol. 139, 112- 117.
pmcid: PMC4587290
pubmed: 26260909
Scott J.M., Lakoski S., Mackey J.R., Douglas P.S., Haykowsky M.J. and Jones L.W. (2013). The potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics. Oncologist 18, 221-231.
pmcid: PMC3579607
pubmed: 23335619
Shattuck D.L., Miller J.K., Carraway K.L. 3rd. and Sweeney C. (2008). Met receptor contributes to trastuzumab resistance of Her2- overexpressing breast cancer cells. Cancer Res. 68, 1471-1477.
pubmed: 18316611
Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A. and McGuire W.L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182.
pubmed: 3798106
Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J. nand Norton L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792.
pubmed: 11248153
Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., Mackey J., Glaspy J., Chan A., Pawlicki M., Pinter T., Valero V., Liu M.C., Sauter G., von Minckwitz G., Visco F., Bee V., Buyse M., Bendahmane B., Tabah-Fisch I., Lindsay M.A., Riva A., Crown J. and Breast Cancer International Research Group (2011). Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365, 1273-1283.
pmcid: PMC3268553
pubmed: 21991949
Sodergren S.C., Copson E., White A., Efficace F., Sprangers M., Fitzsimmons D., Bottomley A. and Johnson C.D. (2016). Systematic review of the side effects associated with anti-HER2-targeted therapies used in the treatment of breast cancer, on behalf of the EORTC quality of life group. Target Oncol. 11, 277-292.
pubmed: 26677846
Sorace A.G., Quarles C.C., Whisenant J.G., Hanker A.B., McIntyre J.O., Sanchez V.M. and Yankeelov T.E. (2016). Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results. Breast Cancer Res. Treat. 155, 273-284.
pmcid: PMC4833210
pubmed: 26791520
Spielmann M., Roche H., Delozier T., Canon J.L., Romieu G., Bourgeois H., Extra J.M., Serin D., Kerbrat P., Machiels J.P., Lortholary A., Orfeuvre H., Campone M., Hardy-Bessard A.C., Coudert B., Maerevoet M., Piot G., Kramar A., Martin A.L. and Penault-Llorca F. (2009). Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J. Clin. Oncol. 27, 6129-6134.
pubmed: 19917839
Untch M., Muscholl M., Tjulandin S., Jonat W., Meerpohl H.G., Lichinitser M., Manikhas A.G., Coumbos A., Kreienberg R., du Bois A., Harbeck N., Jackisch C., Müller V., Pauschinger M., Thomssen C., Lehle M., Catalani O. and Lück H.J. (2010). First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. J. Clin. Oncol. 28, 1473-1480.
pubmed: 20177030
Urruticoechea A., Rizwanullah M., Im S.A., Ruiz A.C.S., Lang I., Tomasello G., Douthwaite H., Badovinac Crnjevic T., Heeson S., Eng-Wong J. and Muñoz M. (2017). Randomized Phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy. J. Clin. Oncol. 35, 3030- 3038.
pubmed: 28437161
van de Vegte Y.J., van der Harst P. and Verweij N. (2018). Heart rate recovery 10 seconds after cessation of exercise predicts death. J. Am. Heart. Assoc. 7, 008341.
pmcid: PMC6015434
pubmed: 29622586
Visser A., van de Ven E.M. Ruczynski L.I., Blaisse R.J., van Halteren H.K., Aben K. and van Laarhoven H.W. (2016) Cardiac monitoring during adjuvant trastuzumab therapy: Guideline adherence in clinical practice. Acta Oncol. 55, 423-429.
pubmed: 26217988
Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J. and Press M. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726.
pubmed: 11821453
von Minckwitz G., du Bois A., Schmidt M., Maass N., Cufer T., de Jongh F.E., Maartense E., Zielinski C., Kaufmann M., Bauer W., Baumann K.H., Clemens M.R., Duerr R., Uleer C., Andersson M., Stein R.C., Nekljudova V. and Loibl S. (2009). Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J. Clin. Oncol. 27, 1999-2006.
pubmed: 19289619
Vu T. and Claret F.X. (2012). Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front. Oncol. 2, 62.
pmcid: PMC3376449
pubmed: 22720269
Wang Q., Zhang X., Shen E., Gao J., Cao F., Wang X., Li Y., Tian T., Wang J., Chen Z., Wang J. and Shen L. (2016). The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer. Cancer Lett. 380, 20-30.
pubmed: 27317872
Wee P and Wang Z. (2017). Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). 9, 5.
pmcid: PMC5447962
pubmed: 28513565
Wieduwilt M.J. and Moasser M.M. (2008). The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol. Life Sci. 65, 1566-1584.
pmcid: PMC3060045
pubmed: 18259690
Xu Y., Benlimame N., Su J., He Q. and Alaoui-Jamali M.A. (2009). Regulation of focal adhesion turnover by ErbB signalling in invasive breast cancer cells. Br. J. Cancer 100, 633-643.
pmcid: PMC2653743
pubmed: 19190626
Yang G.Y., Guo S., Dong C.Y., Wang X.Q., Hu B.Y., Liu Y.F., Chen Y.W., Niu J. and Dong J.H. (2015). Integrin alphavbeta6 sustains and promotes tumor invasive growth in colon cancer progression. World J. Gastroenterol. 21, 7457-7467.
pmcid: PMC4481440
pubmed: 26139991
Zhang Y., Zhang J., Liu C., Du S., Feng L., Luan X., Zhang Y., Shi Y., Wang T., Wu Y., Cheng W., Meng S., Li M. and Liu H. (2016). Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells. Cancer Lett. 382, 176-185.
pubmed: 27597738